



MicroPort NeuroTech Officially Opened


Dec 12, 2012, Shanghai -- MicroPort NeuroTech (Shanghai) Co., Ltd., (Shanghai International Medical Zone), was officially launched with an opening ceremony.

2012 Medical Equipment Quality Forum Held Successfully

Nov 24, 2012: Shanghai Medical Equipment Quality Forum was held successfully at MicroPort. The theme of the forum this year was "Synergy & Progress".

Patent of MicroPort Won China Patent Honorable Mention

Nov 16, 2012, Shanghai -- The 14th China Patent Award announced that the drug eluting stent (DES) -- {Patent no: ZL200410053179.3} declared by MicroPort, won China Patent Honorable Mention.



Contents

MicroPort NeuroTech Officially Opened

2012 Medical Equipment Quality Forum Held Successfully

Patent of MicroPort Won China Patent Honorable Mention

MicroPort NeuroTech Officially Opened

Dec 12, 2012, Shanghai -- MicroPort NeuroTech (Shanghai) Co., Ltd., (Shanghai International Medical Zone), was officially launched with an opening ceremony. The Group President: Ms. Yan Zhang, CFO: Mr. Hongbin Sun, CTO: Mr. Qiyi Luo, CMO: Mr. Bo Peng, and Senior Vice President of manufacturing and operation: Mr. Kongrong Karl Pan were in attendance. Mr. Zhiyong Xie, General Manager, addressed the ceremony, encouraging all employees to work hard in contributing toward the future success of this new enterprise and development of the MicroPort NeuroTech platform. Group Executive Committee members and general managers inaugurated the new office building and discussed the future development and products pipeline of the company.

MicroPort NeuroTech's APOLLO is the first intracranial arterial stent system produced in China and it has achieved 65% domestic market share. Also, the WILLIS™ intracranial stent graft system is the first Chinese designed and manufactured stent for the treatment of intracranial aneurysms. WILLIS™ is expected to be approved by SFDA during the first quarter 2013. WILLIS™ clinical application research project "MRA Imaging of Cerebral Aneurysm and Associated Vascular and Interventional Treatment" was awarded first prize by the Ministry of Education for 'Science and Technology Progress' 2012. In addition, the new generation product: Tubridge™, a revascularization device for the treatment of large intracranial aneurysms, is under development, with multi-center, randomized, and controlled clinical trials already begun. Also, MicroPort NeuroTech is pursuing several other cutting-edge projects. Mr. Bo Peng, CMO of the Group and Executive Director said "I hope that all of the employees grow with the Company and make the Company from nothing to something big through hard working."

MicroPort NeuroTech is specialized in developing, manufacturing and marketing medical devices for the treatment of central nervous system related vascular diseases. At present, the enterprise has obtained 31 invention patents, and 11 utility model patents. In

addition, the company is undertaking the "Twelfth Five-Year" National Science and Technology Support Program in the field of Risk Factors Prevention, Treatment, and Rehabilitation of Cerebral Vascular Disease.

Back to Top

2012 Medical Equipment Quality Forum Held Successfully

Nov 24, 2012: Shanghai Medical Equipment Quality Forum was held successfully at MicroPort. The theme of the forum this year was "Synergy & Progress". The forum aims for participants to learn from each other, discuss, cooperate and make progress, bringing together industry specialists and 'enterprise excellence' representatives to share knowledge and 'know how'. The forum was host by MicroPort Vice President of Quality, Mr. Shengqiang Wang and the President Ms. Yan Zhang made a statement and gave an inaugural address.

The forum's main topics of discussion included specialists from various industry backgrounds, sharing their experiences of how to successfully introduce products into the market, with a focus on compliance with domestic and international rules, laws and regulations. The emphases on quality issues and market trends were also discussed. Dr. Gang Yang, Head at Crosby (China), Mr. Yimin Xu, Vice President of Register and Clinical at MicroPort, Dr. Kawamura, Consultant at Otsuka Pharmaceutical, Mr Xinggong Xu, Vice President of Improve Medical, all made presentations on the topic of "Quality Innovation", "Changes of external regulations in the environment and countermeasures", "International requirements of medical equipment quality control" and "Main findings and countermeasures of FDA reviewing China medical equipment enterprises" respectively. In other topics, representatives from medical equipment enterprises were invited to share and discuss their experience of quality management and assurance systems, equipment and material analysis and evaluation, and product cleanliness control.

Disclaimer: The content below is for communication purpose only. Our company and its affiliates do not guarantee to anybody that the information below is complete and up-to-date. Our company and its affiliates do not accept any responsibility for any decision made as a result of relying on the information contained herein.

This was the first Quality Forum hosted by any enterprise in the medical device industry sector. Mr. Shengqiang Wang said: "We are trying to improve the communication among enterprises to share our experience and knowledge. We also expect to make contribution to quality development in China medical devices industry through this forum."

Back to Top

performance in many market including; Thailand, Indonesia, Venezuela, Argentina, Brazil, Peru, the Philippines and so on. Over half a million units of MicroPort DES products have been sold globally to date.

Back to Top

Patent of MicroPort Won China Patent Honorable Mention

Nov 16, 2012, Shanghai -- The 14th China Patent Award announced that the drug eluting stent (DES) -- {Patent no: ZL200410053179.3} declared by MicroPort, won China Patent Honorable Mention. The award was nominated by the local IP Office, the related departments of the State Council, related national guilds, and members of both the Chinese Academy of Sciences and Academy of Engineering. It was judged by the China patent award evaluation committee, and was verified and determined by both the SIPO and WIPO. The award aims to accelerate the development of innovation as a main economic driver for China. The awarding bodies objective being to fully implement China's national and international IP Rights strategy, strengthen Chinese enterprise for technology innovation, and generally promote the innovative high-tech economy.

The award is made in respect of MicroPort's patent for an innovative DES, which prevents the vascular intima becoming excessively thick after angioplasty. The patent is for the unique design of a polymer carrier material for the DES, which more effectively controls the release of Rapamycin and its derivatives. The patent is used in MicroPort's second generation DES -- (Firebird2TM). The coronary Rapamycin elution cobalt-base alloy support system significantly improves products performance in comparison with our first generation DES product -- (FirebirdTM). At present, Firebird2TM has achieved the leading market position China, achieving a dominant market share and internationally has achieved outstanding sales